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1. Introduction 
Recent advancements in genetic research that have elucidated the function of some of the 
rare disease-causing genes have suggested that a large number of genetic disorders with 
widely divergent phenotypes, that were not previously identified as related, may be, in fact, 
highly related in cellular function or common pathways. A classic example of this is the 
recent category of disorders called ciliopathies. Cilia and flagella are ancient, evolutionarily 
conserved organelles that project from cell surfaces to perform diverse biological roles, 
including whole-cell locomotion; movement of fluid; chemo-, mechano-, and 
photosensation; and sexual reproduction. Over the past ten years, several studies 
demonstrated the connections between cilia, basal bodies and human diseases with a wide 
phenotypic spectrum, including randomization of body symmetry, obesity, cystic kidney 
diseases and retinal degeneration. Defects in ciliary structure or function can lead to a 
broader set of developmental and adult phenotypes, with mutations in ciliary proteins now 
associated with nephronophthisis, Joubert Syndrome, Meckel-Gruber Syndrome, Bardet- 
Biedl Syndrome, and Alström Syndrome (ALMS), [Badano et al., 2006]. Further study of 
these diverse ciliopathies could lead to an understanding of the phenotypic patterns that 
could potentially have predictive and therapeutic value. Alström Syndrome (ALMS; MIM 
#203800), first described by Carl-Henry Alström, in 1959 [Alström et al., 1959], is a rare 
condition that affects many body systems. ALMS is characterized by a constelation of 
serious or life-threatening medical problems including sensory deficits, obesity, type 2 
diabetes mellitus, and multiple organ failure. The signs and symptoms of ALMS vary in 
severity, and not all affected individuals have all of the characteristic features of the 
disorder, making the diagnosis more difficult. Additionally, many of the signs and 
symptoms of this condition begin in infancy or early childhood, although some appear later 
in life. The major phenotypes usually observed in children with ALMS include cone–rod 
retinal dystrophy beginning in infancy and leading to juvenile blindness, sensorineural 
hearing impairment, insulin resistance, and obesity, and congestive heart failure (CHF) due 
to dilated cardiomyopathy (DCM). As patients reach adolescence, more of the major 
phenotypes develop, including type 2 diabetes mellitus, hypertriglyceridemia, 
hypothyroidism, and short adult stature. Males and females have hypogonadism and are 
infertile. Pulmonary, hepatic, and renal phenotypes are progressive [Marshall et al. 1997, 
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2005]. The primary cause of mortality among young affected patients is cardiac involvement 
from dilated cardiomyopathy whereas renal failure is the major cause of death among the 
older subgroup [Marshall et al., 1997]. Systemic fibrosis is commonly observed [Marshall et 
al., 2005]. About 700 affected individuals have been identified worldwide. The estimated 
prevalence is of <1: 5,000,000 [JD.Marshall, Personal communication]. Ethnically or 
geographically isolated populations have a higher-than-average frequency of Alström 
syndrome [Deeble et al., 2000 & Ozgül et al., 2007]. 
2. Diagnosis 
2.1 Clinical diagnosis 
The diagnosis of ALMS is usually established by clinical findings. Diagnosis may be delayed 
because some features begin at birth and others emerge as the child develops. Diagnosis can 
also be difficult due to variable expression of the severity of the clinical features both within 
and among families. It is important to note that, although some of the features are seen 
frequently, affected individuals may not have all of the symptoms discussed below. 
2.1.1 Major features 
Cone-rod dystrophy. The first symptoms are pendular or searching nystagmus and extreme 
photodysphoria or light sensitivity. The retinal dystrophy in ALMS often develops within a 
few weeks after birth and virtually all children exhibit low vision within the first year of life 
[Malm et al., 2008; Russell-Eggitt et al., 1998]. Fundus examination in the first decade may be 
normal or may show a pale optic disc and narrowing of the retinal vessels. 
Electroretinography (ERG), required to establish the diagnosis of cone-rod dystrophy, is 
abnormal from birth, eventually with impairment of both cone and rod function. Rod 
function is preserved initially but deteriorates as the individual ages. By 9 – 10 years of age, 
visual acuity is severely impaired. There is increasing constriction of visual fields, leading to 
total blindness with no light perception by age 16- 20 years [Marshall et al., 2007a, Michaud 
et al., 1996]. The severity and age of onset of the retinal degeneration vary among ALMS 
patients [Malm et al., 2008]. Retinal changes include attenuated vessels, pale optic discs, and 
partial atrophy of the retinal pigment epithelium. Pathological studies show a reduction of 
cell layers in the posterior retina and depletion of peripheral cells, the outer nuclear layer, 
and photoreceptors [Sebag et al., 1984, Vingolo et al., 2010]. Exudative retinopathy was 
described in Alström Syndrome [Gogi et al., 2007]. Vision may be aided in the first few years 
if the child is given prescription dark, red-tinted glasses. Cataract is a common finding and 
some patients might transiently benefit from its treatment/removal [Marshall et al., 2005, 
2007, Satman et al., 2002]. 
Progressive bilateral sensorineural hearing impairment   
Most patients develop mild-to-moderate bilateral sensorineural hearing loss in early 
childhood (<10 years) that is slowly progressive, particularly in the high-frequency range 
[Van den Abeele et al., 2001; Welsh 2007]. There is a high incidence of otitis media and fluid 
retention along with a high susceptibility to glue ear, which compounds the existing 
sensorineural impairment [Marshall et al. 2005, Michaud et al., 1997]. Hearing loss may be 
detected as early as age one year in some patients, although wide differences in acuity exist. 
Although bilateral hearing aids generally benefit most children, about 10% progress to 
profound deafness and must rely on tactile signing for communication [Marshall et al., 
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2007a]. There is evidence that vestibular function is abnormal in some patients. [Möller, 
2005]. Because hearing loss develops gradually and the onset is post-lingual, children 
typically do not experience the speech problems often associated with deafness. These early 
changes in neurosensory capabilities can have tremendous impact not only on the social 
development of the child but also on his/her adaptation to the external environment [Joyet 
al., 2007, Van den Abeele et al., 2001].  
Obesity 
Obesity in Alström Syndrome is an early and consistent feature observed in nearly all 
affected children [Marshall et al., 2005, 2007a]. Body Mass Index (kg/m2) is typically greater 
than 25 or >95th centile, with the distribution of adipose tissue predominantly viscerally and 
subcutaneously [Paisey et al., 2008]. Birth weight is normal, but rapid weight gain usually 
begins at approximately 6 months to 1 year of age. In some individuals body weight tends to 
normalize, decreasing into the high-normal to normal range after adolescence. The 
moderation of weight does not seem to be correlated with the onset of other serious 
complications such as CHF, T2DM, or renal failure [Minton et al., 2006]. Wide shoulders, a 
barrel chest, a 'stocky' build, and truncal obesity are typical [Marshall et al., 2007a]. 
However, both waist circumference and body fat percentage (as measured using dual-
energy X-ray absorptiometry) negatively correlated with age, and was independent of Body 
Mass Index, indicating the possible recruitment of more metabolically active fat stores 
[Minton et al., 2006]. The presence of hyperphagia has been controversial, although both 
hyperphagia and food obsession are common anecdotal complaints [Marshall et al., 1997, 
2005].  
Growth and development 
Children grow rapidly and are initially tall for their age with a height >50th centile, with 2–3 
years advanced bone age prior to puberty. However, early closure of the growth plates 
results in height below the 50th centile by age 14–16 years [Michaud et al., 1996]. Thoracic 
and lumbar scoliosis and kyphosis commonly develop in the early teenage years and can 
progress rapidly. Many patients have a 'buffalo hump' of increased fatty tissue above the 
shoulders [Marshall et al., 2005, 2007a]. Abnormalities of the insulin-like growth factor 
system (IGFs) of affected patients have been demonstrated [Maffei et al., 2007, Mihai et al., 
2008, 2009]. Yet, the exact reasons for short stature remain to be determined. 
Dilated cardiomyopathy  
DCM can occur at any age, but is seen most typically during infancy. Onset, progression, 
and clinical outcome of the DCM vary, even within families [Hoffman et al., 2005, Makaryus 
et al., 2003]. Approximately 40% of affected infants have a transient but severe DCM with 
onset between age three weeks and four months [Marshall et al., 2005, Worthley & Zeitz, 
2001]. Most of these children survive and make an apparently full recovery in infancy. The 
proportion of those with ALMS who develop infantile-onset DCM may be underestimated 
because some infants who succumb early may have undiagnosed Alström syndrome.  
A subset of 10-15% of patients does not experience infantile DCM, but develop 
cardiomyopathy for the first time as adolescents or adults. These patients present with a 
progressive restrictive cardiomyopathy [Worthley & Zeitz, 2001], identified between the 
teens to late 30s. Although DCM is the most common underlying cause of death in the 
infantile period, survival for children with infantile-onset tends to be better than that for 
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adult-onset. Marshall et al showed that while one-third of adult-onset DCM patients died, 
~74% of infantile-onset DCM patients survived [Marshall et al., 2005]. As these children 
grow older, their cardiac function tends to be low-normal, and they remain at risk for a 
recurrence of CHF as adolescents or adults, with a poor prognosis. Postmortem myocardial 
fibrosis has been described [Minton et al., 2006]. Cardiac magnetic resonance imaging 
suggests myocardial fibrosis may be present both in clinically affected and asymptomatic 
individuals [Loudon et al., 2009]. 
Augmented aortic systolic pressure may also contribute to heart failure [Smith et al., 2007]. 
 DCM in infants in the presence of nystagmus and photophobia should be a strong indicator 
of a diagnosis of ALMS. 
Pulmonary disease  
Chronic respiratory illness is one of the most frequent complaints and ranges in severity 
from frequent bronchial infections to chronic asthma, sinusitis/bronchitis, alveolar 
hypoventilation, and frequent episodes of pneumonia. The chronically inflamed airways are 
hyper-reactive and highly sensitive to triggering or irritating factors. In some patients, as 
inflammation continues, the lungs are infiltrated by fibrotic lesions and moderate to severe 
interstitial fibrosis has been reported [Marshall et al., 2005]. Pulmonary disease can be quite 
severe and include chronic obstructive pulmonary disease and pulmonary hypertension, 
secondary to pulmonary fibrosis. Respiratory infections with sudden reduced blood oxygen 
saturation have triggered sudden death. Acute hypoxia and acute respiratory distress 
syndrome in some older patients probably results from a combination of pulmonary fibrosis 
and severe scoliosis [Khoo et al., 2009; Florentzson et al., 2010].   
Insulin resistance/type 2 diabetes mellitus 
Two of the earliest metabolic changes in ALMS, insulin resistance and hyperinsulinemia, 
have been observed in patients as young as 1 year of age, sometimes before the onset of 
obesity [Marshall et al., 2005, 2007a]. Most children will eventually develop T2DM, some as 
early as age 4, but there is wide variability in the age of onset. The median age of onset is 16 
years. T2DM in Alström syndrome is the result of tissue resistance to the actions of insulin, 
as demonstrated by an elevated plasma insulin concentration and glucose intolerance that 
usually present in childhood [Marshall et al., 2005, 2007a]. Acanthosis nigricans, a common 
feature in ALMS, consistent with severe insulin resistance, obesity, hyperinsulinemia, is 
described in about one-third of patients, whether or not they have diabetes [Marshall et al., 
2005, 2007a]. However, in a small study of 12 unrelated individuals with ALMS, severe 
childhood obesity, BMI and waist circumference decreased with age, whereas insulin 
resistance increased [Minton et al., 2006]. Interestingly, ALMS patients with T2DM do not 
appear to develop typical peripheral sensory neuropathy symptoms and maintain good 
protective sensation despite comparable hyperglycemia and dyslipidemia seen in other 
types of diabetes. This suggests the ALMS1 mutations might in some way protect against 
hyperglycemia-induced sensory neuropathy [Paisey et al., 2009]. However, studies of nerve 
conduction in these patients are needed to confirm these findings.  
Hepatic disease  
 Nearly all patients with ALMS may have some degree of liver involvement that first 
presents with fatty liver. Initially, overt clinical manifestations are absent, but transaminases 
and gamma-glutamyl transpeptidase could be elevated. Ultrasound may show evidence of 
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steatosis, steatohepatitis, and enlarged liver and spleen, which can progress in ALMS 
patients as they grow older. In some individuals, hepatic inflammation and fibrosis 
develops, with a highly variable age of onset, clinical course, and prognosis. As the disease 
progresses, liver function tests are further disturbed with altered prothrombin values or 
elevated International normalized ratio (INR) and ammonia. Progression to hepatic failure 
can occur in childhood [Quiros-Tejeira et al., 2001], but usually worsens in the second to 
third decades. Portal hypertension, hepatosplenomegaly, cirrhosis, esophageal varices, 
ascites, and liver failure are among the late clinical signs and the upper gastro-intestinal 
hemorrhage due to portal hypertension is a cause of death in some patients [Marshall et al., 
2005, 2007a]. It is not yet known why the hepatic function becomes serious in some children, 
while others remain stable [Awazu et al., 1995, 1997, Connolly et al., 1991 & Marshall et al., 
2005].  
Liver biopsies and postmortem examination have revealed varying degrees of 
steatohepatitis, hepatic fibrosis, cirrhosis, chronic nonspecific active hepatitis with 
lymphocytic infiltration, patchy necrosis, [Marshall et al., 2005, Quiros-Tejeira et al., 2001]. 
Macrovesicular steatosis can be present or absent [Marshall et al., 2005]. Other 
gastrointestinal manifestations include upper gastrointestinal pain, chronic diarrhea, 
constipation, cecal volvulus, and gastroesophageal reflux [Marshall et al., 2005; Khoo et al., 
2009]. 
Renal disease  
The age of onset, progression rate, and severity of renal involvement are variable in ALMS, 
but most often becomes serious in adolescents or adults. Slowly progressive nephropathy, 
progressive glomerulofibrosis, and a gradual destruction of the kidneys are a major feature 
in adult patients with ALMS. Whether hypertension is a consequence of or contributes to 
renal dysfunction is uncertain, but it is present in ~30% of individuals [Marshall et al., 2005]. 
Patients may have symptoms ranging from chronic, mild kidney dysfunction to end-stage 
renal failure. Histopathologic changes include hyalinization of tubules and interstitial 
fibrosis [Goldstein and Fialkow, 1973, Marshall et al., 2005, 2007a]. There is evidence 
suggesting that the position of the alteration in ALMS1 may play a role in the severity of the 
renal disease [Marshall et al., 2007b]. 
Hypogonadotropic hypogonadism  
Male hypogonadotropic hypogonadism results in low plasma testosterone secondary to low 
plasma gonadotropin concentration. Males often have a small penis and testes, usually with 
gynecomastia in adolescence. Atrophic fibrotic seminiferous tubules are described [Marshall 
et al., 2007a]. Secondary sexual characteristics such as axillary and pubic hair are normal in 
both males and females. In female adolescents, sexual development usually progresses 
normally and menarche is not delayed (average age 12 years). In a few patients, precocious 
puberty has occurred (age 6–10) and breast development has been delayed. The external 
genitalia, uterus, and fallopian tubes are normal, but menstruation is often scant, sporadic, 
or irregular, sometimes accompanied by endometriosis. There can be reduced plasma 
gonadotropin concentrations. Baseline FSH and LH in female adolescents are usually in the 
normal range; however, some evidence of primary hypogonadism has been reported 
[Quiros-Tejeira et al., 2001]. Increased androgen production and hirsuitism are common 
[Kocova et al., 2010]. A relatively high frequency (>20% of female patients) of ovarian cysts 
is reported, which may be associated with obesity and hyperinsulinemia. No ALMS patients 
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have been known to reproduce – the few cases where this is „reported” are in patients 
without a confirmed molecular diagnosis [Boor et al., 1993]. 
Hypertriglyceridemia 
Hyperlipidemia, particularly hypertriglyceridemia, can be present from early childhood. In 
some patients, a sudden, rapid rise in triglycerides places them at risk for pancreatitis 
[Paisey et al., 2009, Wu et al., 2002]. Other features in Alström Syndrome, such as 
hyperinsulinemia, may also contribute to the elevated triglycerides [Maffei et al., 2002, 
2007]. 
2.1.2 Minor features 
Hypothyroidism 
A hypothyroid condition, mostly primary (low free thyroxine (FT4), high thyroid-
stimulating hormone (TSH)), is observed in approximately 20% of patients [Michaud et al., 
1996]. Subclinical hypothyroidisms in about 30% of patients and isolated incidents of 
hyperthyroidism have been observed [Ozgül et al., 2007]. The mechanism of the 
hypothyroidism remains unknown, although it could be hypothesized that fibrotic 
infiltrations in the thyroid gland play a role.  
Dental abnormalities 
Dental anomalies include discolored teeth, gingivitis, a large space between the front teeth, 
and extra or missing teeth [Koray et al., 2001]. 
Hands and feet 
Most children have characteristic wide, thick, flat feet, and short stubby fingers and toes 
with no polydactyly or syndactyly. Rare cases of digit anomalies have been reported 
[Marshall et al., 2007a]. 
Urological dysfunction 
Males and females with ALMS can experience varying degrees of urinary problems. Minor 
symptoms include urinary urgency, difficulty initiating or poor flow, long intervals between 
voiding, incomplete voiding (urinary retention) or abdominal pain before or during 
urination [Marshall et al., 2005]. There can be an unusual changing presentation, switching 
from retention to increased frequency, and incontinence. Recurrent urinary tract infections 
or cystitis are common in both males and females. Urethral strictures have also been 
described and fibrotic infiltrations have been noted histopathologically. A subset of patients 
have developed more severe complications such as marked frequency and urgency, 
incontinence, and significant perineal or abdominal pain requiring surgical intervention 
[Charles et al., 1990, Marshall et al., 2005, 2007a]. Anatomical abnormalities can also occur in 
ALMS, including calyceal deformities, narrowed ureteropelvic angles, dilated ureters, and 
misalignment of the kidneys [Ozgül et al., 2007]. 
Developmental delay  
Although delay of cognitive impairment is not a common feature of ALMS, delay in early 
developmental milestones is seen in ~45% of affected children. Motor milestones, in 
particular sitting, standing, and walking, are typically delayed by 1–2 years and there may 
be deficits in coordination, balance, and fine motor skills. Hearing and vision deficits 
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probably contribute to the early developmental, expressive and receptive language, and 
learning delays seen in many young children with ALMS. Children with a receptive 
language deficit also tend to have an expressive language delay. Intellectual delays and 
behavioral issues in rare cases have resulted in a diagnosis of mental retardation. A range of 
autism-spectrum behavior has been observed in a subset of patients [Marshall et al., 2005, 
2007a]. 
Other neurologic manifestations may include absence seizures and general sleep 
disturbances [Marshall et al., 2005, 2007a]. The frequency of mood and psychiatric disorders 
in ALMS-affected individuals has not been determined [Joy et al., 2007]. 
The combined effect of hearing loss and an accompanying multiple disabilities present a 
unique and complex problem to professionals and parents, different from the problems 
usually associated with any disability alone. A review of the literature yields surprisingly 
little specific information on educational programs for such children. The fact that there are 
many differences among children with multiple disabilities adds to the difficulties of 
providing appropriate programs. 
2.2 Diagnostic criteria in Alström Syndrome  
A major problem in arriving at a diagnosis of ALMS is the high phenotypic heterogeneity 
that can occur even within the same affected family [Ozgül et al., 2007, Hoffman et al., 2005 
& Titomanilo et al., 2004]. Marshall and co-workers [Marshall et al., 2007a] provided a 
comprehensive guidance for diagnostic criteria in their 2007 publication, as summarized 
below: 
 
Birth – 2 years: Diagnosis requires 2 major or 1 major and 2 minor criteria 
Major criteria:  1) ALMS1 mutation in 1 allele and/or family history of Alström   
     Syndrome  
2) Vision pathology (nystagmus, photophobia). 
Minor criteria:  
 
          1) Obesity  
          2) DCM with CHF. 
Other variable 
supportive evidence 
Recurrent pulmonary infections, normal digits, delayed 
developmental milestones. 
 
3–14 years of age: diagnosis requires 2 major criteria or 1 major and 3 minor criteria 
Major criteria:  1) ALMS1 mutation in 1 allele and/or family history of Alström   
     Syndrome  
2) Vision pathology (nystagmus, photophobia, diminished acuity). 
     If old enough for testing: cone dystrophy by ERG. 
Minor criteria:  
 
1) Obesity and/or insulin resistance and/or T2DM  
2) History of DCM with CHF  
3) Hearing loss  
4) Hepatic dysfunction 
5) Renal failure  
6) Advanced bone age 
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Other variable 
supportive evidence 
Recurrent pulmonary infections, normal digits, delayed 
developmental milestones, hyperlipidemia, scoliosis, flat wide 
feet, hypothyroidism, hypertension, recurrent urinary tract 
infections, growth hormone deficiency 
 
15 years – adulthood: 2 major and 2 minor criteria or 1 major and 4 minor criteria 
Major criteria:  1) ALMS1 mutation in 1 allele and/or family history of Alström   
     Syndrome  
 
2) Vision pathology (history of nystagmus in infancy/childhood,  
    legal blindness, cone and rod dystrophy by ERG). 
 
Minor criteria:  
 
1) Obesity and/or insulin resistance and/or T2DM 
2) History of DCM with CHF.  
3) Hearing loss  
4) Hepatic dysfunction  
5) Renal failure  
6) Short stature  
7) Males: hypogonadism. Females: irregular menses 
and/or hyperandrogenism 
Other variable 
supportive evidence 
Recurrent pulmonary infections, normal digits, history of 
developmental delay, hyperlipidemia, scoliosis, flat wide feet, 
hypothyroidism, hypertension, recurrent urinary tract 
infections/urinary dysfunction, growth hormone deficiency, 
alopecia. 
Table 1.  
In conclusion, ALMS is  a very complex disorder, being characterized by a constellation of 
progressive and highly variable disease symptoms. Diagnosis is made on the basis of clinical 
features observed, usually without genetic confirmation. Delay of onset of some of the 
characteristic features (type 2 diabetes mellitus, DCM/chronic heart failure, hepatic 
dysfunction, pulmonary, and renal disease) makes early differential diagnosis very difficult 
in young children, as many of the cardinal features do not become apparent until the 
teenage years. As the child grows, the characteristic pattern of ALMS evolves and the 
clinical picture becomes clearer. 
2.3 Age of onset and incidence of common features of Alström Syndrome 
Marshall and co-workers [Marshall et al., 2005] described the age of onset and the incidence 
of common features of Alstrom syndrome. Cone-rod dystrophy was diagnosed in 100% of 
ALMS patients between birth and 15 months. Obesity usually begins to develop during the 
first year, birth weight being normal. Hearing loss is progressive and presents in 88% of 
cases during the first 9 years. Dilated cardiomyopathy could be diagnosed in 42% of infants 
under 4 months of age. In adolescents and adults the pattern is often restrictive 
cardiomyopathy, with an overall incidence of 18%. Insulin resistance/type 2 diabetes can be 
diagnosed in children as young as 4 years of age. While urologic dysfunction can be seen at 
any age, chronic renal failure begins in adolescents and adults. About 25-30 % of ALMS 
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patients are diagnosed with developmental delay, based on the assessment of early 
development milestones. Liver involvement develops variabily, between 8 and 30 years of 
age, in 23-98% of patients. Over 98% are diagnosed with short stature after puberty or in 
adulthood. Among the endocrine abnormalities, hypogonadotropic hypogonadism was 
diagnosed in 78% of males. 
2.4 Genetic diagnosis 
Alström Syndrome is the consequence of recessively inherited mutations in a single gene, 
ALMS1, located on the short arm of chromosome 2 [Collin et al., 2002, Hearn et al., 2002]. 
Parents are obligate carriers of a single copy of the altered gene and have no reported 
heterozygous phenotypic characteristics. Males and females are affected with equal 
probability (1:1 ratio). Although the incidence is greater in isolated or consanguineous 
communities, there is no one ethnic group more likely to carry ALMS1 mutations [Marshall 
et al, 2007a]. 
ALMS1 is comprised of 23 exons. The longest ALMS1 transcript potentially encodes a 461 
kDa protein of 4169 amino acids. Exon 1 contains a tract of glutamic acid residues (aa 13–29), 
followed by a stretch of seven alanine residues (aa 30−36) [Collin et al., 2002, Hearn et al., 
2002]. Exon 8, a large 6-kb exon, contains a large tandem repeat domain encoding 34 
imperfect repeats of 45–50 amino acids. This domain constitutes 40% of the protein, a short 
polyglutamine segment, a leucine zipper domain and a conserved motif near the C-
terminus. 
The ALMS1 protein is ubiquitously expressed and at least one isoform localizes to 
centrosomes and basal bodies of ciliated cells, perhaps playing an important role in cilia 
function and intraflagellar transport [Collin et al., 2005, Hearn et al., 2005; Knorz et al., 2010]. 
RNA interference knockdown experiments indicate that a total lack of ALMS1 impairs cilia 
formation [Li G et al., 2007]. 
To date, the mutations reported in ALMS1 have been nonsense and frameshift variations 
(insertions or deletions) and one reciprocal translocation that are predicted to cause 
premature protein truncation [Collin et al., 2002, Hearn et al., 2002]. Since 2002, more than 
100 different mutations in ALMS1 have been identified. The variants are primarily clustered 
in exons 16, 10, and 8, but less common mutations also occur in exons 12 and 18 [Marshall et 
al., 2007a; Joy et al., 2007; Pereiro, et al., 2010]. Founder effects are reported in families of 
English and Turkish descent. In addition, numerous single-nucleotide polymorphisms have 
been identified, the functional significance of which is unclear [Marshall et al., 2007a]. The 
mechanisms by which disease alleles of ALMS1 cause the various pathologies observed in 
Alström Syndrome remain unknown and identification of pathogenic mutations in ALMS1 
has not led to any genotype-specific treatments [Hearn et al., 2005, Kinoshita et al., 2003, Li 
G et al., 2007, Minton et al., 2006 & Patel et al., 2006]. 
ALMS1 RNA is widely expressed by many tissues. Splice variants have been identified from 
human brain and testis which may suggest differing functions of theALMS1 protein 
between organs [Hearn et al., 2002].  
The ubiquitous expression of ALMS1 correlates with the wide range of organ dysfunction in 
ALMS and suggests that the C-terminal portion of the Alms1 protein that is missing in 
ALMS patients plays a critical role in disease causation [Girard & Petrovsky, 2010]. Because 
ALMS1 is a very large gene, complete sequencing is time consuming and expensive. 
Therefore, we recommend a screening strategy that targets the regions of ALMS1 where 
most of the mutations are seen (exons 16, 10, part of 8). If no mutation is identified in these 
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areas, the remaining genomic regions can be sequenced on a research basis. The sensitivity 
of this approach is approximately 65%, that is, in about 42% of all patients both mutations 
will be detected, in about half of the patients, only one of the two mutations will be found, 
and in about 10% of the patients, none of the mutations will be found. The recent 
development of an-ALMS mutation array to detect known mutations in ALMS1 (Asper 
Biotech (www.asperbio.com) can be used as an efficient and cost-effective first pass 
screening for known mutations ALMS1 and 10 known Bardet-Biedl Syndrome (BBS) genes 
[Pereiro et al.,2010]. New technological developments including target capture and next 
generation sequencing will offer the possibility of efficient and cost-effective identification 
of novel ALMS1 mutations and for carrier testing [Bell et al., 2011]  
The possible results of genetic testing must be interpreted within the context of the clinical 
picture [Marshall et al., 2007a]:  
• 2 mutations identified in ALMS1. Diagnosis: ALMS. 
• 1 mutation in ALMS1 together with clinical signs of Alström Syndrome. Diagnosis: very 
strong evidence for the confirmation of ALMS (although about 0.25% of all healthy 
individuals could also show this result). 
• No ALMS1 mutation identified. This does not exclude the diagnosis, in the presence of 
clinical manifestations suggestive for ALMS.  
3. Differential diagnosis of Alström Syndrome [Marshall et al., 2007a] 
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hearing loss
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Diabetic 
nephropathy 
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No 
No 
Yes, abdominal 
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Diabetes 
T2DM (90%) 
T2DM (5–15%) 
No 
No 
Diabetes insipidus, 
insulin-dependent 
diabetes mellitus 
No 
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Hypogonadism 
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No 
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Mental 
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severe delay 
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Urologic
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Urinary at
  
  
Orthopedic 
Short fingers, 
wide flat feet, 
scoliosis 
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and syndactyly 
Normal 
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Narrow hands 
and feet, 
tapered fingers 
Postaxial 
polydactyly, 
scoliosis 
Head 
No 
High-arched 
palate, 
hypodontia 
No 
No 
No 
Characteristic 
facial features 
Absent incisors, 
microcephaly, 
characteristic 
facial features 
Genetic 
ALMS1 (2p13) 
BBS1, BBS2, ARL6/BBS3, BBS4,  BBS5, MKKS/BBS6, 
BBS7, TTC8/BBS8, B1/BBS9, BBS10, TRIM32/BBS11,  
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COH1 (8q22) 
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4. Management 
There is no treatment at this time that can cure ALMS or prevent or reverse the medical 
complications.  
Early diagnosis is important to allow counseling of parents and institution of appropriate 
supportive medical treatment. In the absence of specific therapy to correct the underlying 
genetic defect, ALMS remains a progressive disease and regular intensive medical 
management is essential to track progression and to anticipate the emergence of new 
symptoms and disease manifestations.  
Cardiac, renal and liver review should be routinely performed in all ALMS patients, even if 
asymptomatic. 
The main causes of death in ALMS are from cardiomyopathy, pulmonary, kidney or liver 
failure [Marshall et al., 2005, Benso et al., 2002]. In the end stage, multiple organs are 
compromised, and sudden multiple organ failure is common.  
4.1 Management of sensory deficits 
Vision and hearing loss can impact the social and educational success of the child, so, 
management of the multiple sensory deficits in young children diagnosed with ALMS and 
social support at school are crucial [Marshall et al., 2007a]. 
4.1.1 Rod-cone dystrophy  
Photophobia and nystagmus are serious problems, particularly in younger children. Regular 
ophthalmologic evaluations should be sought as soon as possible [Gogi et al., 2007]. Red-
tinted prescription glasses are helpful in alleviating the distress children experience in bright 
lighting. No therapy for the progressive vision loss exists, but early evaluation of visual 
acuity facilitates the provision of visual aids and helps prepare the child for a future with 
little or no sight. Educational planning should anticipate future blindness, therefore, early 
mobility training and Braille or other non-visual language skills is critically important for 
the learning environment of the child. Computing skills (including voice recognition and 
transcription software), and the use of large print reading materials early on while vision is 
still present are crucial [Marshall et al 2010]. 
4.1.2 Progressive sensorineural hearing loss  
Hearing evaluation should begin early in childhood, as otoacoustic emissions and 
audiometry may reveal subclinical hearing loss. Conductive loss is common in children as a 
result of chronic otitis media. Hearing can usually be effectively managed with bilateral 
digital hearing aids, but should be monitored regularly. Myringotomy has been helpful in 
individuals with recurrent "glue ear". Cochlear implantation has benefitted some patients, 
but surgeons should be aware of the risk of sudden hypoxia for these patients undergoing 
procedures requiring anesthesiology [Florentzson et al., 2010]. 
4.2 Obesity. Insulin resistance/Type 2 diabetes 
The major clinical treatment focus is on control of obesity and T2DM.  
Candidate therapeutic intervention to treat severe insulin resistance and possibly prevent 
the transition from insulin resistance to overt diabetes include insulin-sensitizing drugs 
(metformin and thiazolidinediones) [Sinha et al., 2007 as cited in Atabek, 2007, Nag S et al., 
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2003] and beta cell-preserving drugs (incretins, thiazolidinediones) [Pagano et al., 2008, 
Paisey et al., 2009]. However, this requires close monitoring of liver, cardiac, and renal 
function. Glitazones are added to further reduce insulin resistance but must be avoided in 
the presence of active or treated heart failure and when the serum creatinine concentration 
exceeds 200 µmol/L. Exenatide, an incretin mimetic, an injectable analogue of glucagon-like 
peptide 1(GLP- 1) could be promising in adults with ALMS.  
Weight loss exercises should play a pivotal role in weight reduction plan for ALMS patients, 
as in other patients diagnosed with dibetes and obesity, although could be challenging. 
Walking, hiking, biking, and swimming with partners and adaptations for the blind have 
been helpful. Peripheral sensor-motor neuropathy is a common complication of T2DM, but 
in a small clinical testing study in ALMS, a full preservation of protective foot sensation was 
demonstrated [Paisey et al., 2009]. The responsiveness to treatment of hyperglycemia is 
variable. Younger patients rarely require insulin, but some patients require insulin in very-
high doses long term [Marshall et al., 2007a].  
Caloric restriction helps control obesity, glucose tolerance and hyperinsulinemia [Holder et 
al., Lee et al., 2009 & Paisey et al. 2008], although as with children with other genetically 
acquired obesity syndromes, dietary compliance may be a major problem. Reducing dietary 
carbohydrates may prove more effective than fat restriction in control of hyperglycemia and 
hyperinsulinemia [Paisey et al., 2008]. No clinical experience has been reported in ALMS of 
use of specific appetite suppressant medication, such as duramine or sibutramine.  
4.3 Hypertriglyceridemia 
Insulin resistance, T2DM, dyslipidaemia and associated cardiac, renal and hepatic 
consequences coexist from a young age with considerable morbidity and reduction in life 
expectancy. ALMS patients can have potentially harmfully increased lipid levels. 
Hypertriglyceridemia can often be normalized by diet, exercise and Metformin. Some 
patients with severe hypertriglyceridemia responded to a combination of low-fat diet, 
statins and nicotinic acid [Paisey et al., 2004], very little data existing, however, about the 
safety and efficacy of such treatments before puberty. 
Early introduction of preventative nutrition with low-carbohydrates, exercise and drug 
therapies (niacin extended-release and incretins) in ALMS could be beneficial [Paisey, 
2009].  
Pancreatitis should be treated as in the general population, but it is a challenge to treat a 
patient with multiple system involvement such as ALMS patients [Marshall et al., 2010, 
Paisey, 2009, Wu WC et al., 2003].  
4.4 Impaired growth hormone (GH)-IGF1 axis function 
There is an impaired growth hormone (GH)-IGF1 axis function in ALMS (Maffei et al., 2000, 
2002), therefore, therapy with recombinant human Growth Hormone (rhGH) has been 
attempted in a small series of patients and isolated cases and has been reported to be 
beneficial for some metabolic parameters. Demonstrating growth hormone deficiency in a 
patient with ALMS, Tai and co-workers assessed the metabolic effects of growth hormone 
therapy concluding that rhGH therapy might have beneficial effects on body composition, 
liver fat content, lipid profiles, and insulin resistance in Alström Syndrome patients, with 
improvement of the glucose homeostasis [Tai et al., 2003]. Also, Maffei et al. found a 
reduction of ALS (acid labile subunit) and the increase of IGFBP-2 as expression of growth 
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hormone deficiency condition in 15 young adults with ALMS [Maffei et al., 2000]. RhGH 
therapy should be considered still investigational [Marshall et al. 2007a]. Several studies 
are needed to prove that this therapy is cost-effective and without risk in patients with 
ALMS and severe insulin resistance.  
4.5 Cardiomyopathy 
Patients diagnosed with ALMS should be regularly monitored for cardiac function by 
echocardiography, even if asymptomatic [Makaryus et al., 2002, Zubrow et al., 2006]. 
Several authors [Loudon et al., 2009, Makaryus et al., 2007] stated the importance of serial 
cardiac magnetic resonance scanning in diagnosis of the underlying disease progression and 
responses to treatment. Long-term angiotensin-converting enzyme inhibition is indicated for 
the patient with cardiomyopathy. Many patients respond to other medications, which 
favorably affect heart function, such as diuretics, digitalis, beta-blockers, and spironolactone. 
Whether cardiac transplantation is a viable option is yet to be determined, due to the 
multisystemic involvement, particularly pulmonary, endocrine, and renal function. There 
has been one successful heart-lung transplantation reported in an adolescent patient with 
Alström Syndrome, but with no T2DM or significant renal failure [Görler et al., 2007]. A 
second successful heart transplant has been achieved in an infant prior to the onset of the 
endocrinological and renal disturbances [JD Marshall, Personal communication]. 
4.6 Thyroid 
Replacement therapy with L-thyroxin, when needed, is very effective and well-tolerated in 
the majority of patients.  
Thyroid function should be monitored closely in critical hospital settings [Marshall et al., 2007].  
4.7 Urologic 
Lack of coordination between bladder and urine outflow (detrusor-urethral dyssynergia) 
can be helped by intermittent self-catheterization of the bladder. Ileal diversion may be 
necessary in rare patients [Marshall et al., 2007; Charles, et al. 1990]. 
4.8 Hypogonadotropic hypogonadism 
If abnormalities in pubertal development or menstrual abnormalities are present, the 
affected individual should be referred to an endocrinologist with expertise in sexual 
developmental abnormalities. Primary hypogonadism in ALMS males result in low levels of 
testosterone, treated with weekly or twice monthly injections of testosterone from puberty 
onwards. Treatment with cyclical oestrogen and progesterone is important and effective to 
regulate menstrual cycle and development.  
4.9 Hepatic disease  
 Liver function parameters should be routinely monitored, beginning in childhood. Portal 
hypertension and varices may be aggressively treated with beta-blockers and sclerotherapy 
of the esophageal veins. Variceal banding could be useful to prevent upper gastro-intestinal 
hemorrhage. A transjugular intrahepatic portosystemic shunt (TIPS) is used to treat the 
complications of portal hypertension, when the patient has failed to respond to previous 
therapeutic measures. Patients with significant portal hypertension should be evaluated 
early for liver transplantation [Marshall et al., 2007]. 
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4.10 Renal disease  
Because renal insufficiency develops slowly as the patient ages, regular testing of renal 
function (plasma electrolytes, blood urea nitrogen, creatinine, and urea) is important, 
particularly in the older patient. Baseline values should be taken in children. Management of 
hypertension, a low-sodium and low-protein diet, avoidance of nephrotoxic drugs are very 
important in the preservation of renal function, as well as angiotensin-converting enzyme  
inhibitors prescribed according to general guidelines. Fibrosis and glomerulosclerosis in the 
kidneys may lead to eventual renal failure, requiring dialysis. Renal transplantation has 
been successful in several patients, although can be contraindicated in the presence of other 
complications including morbid obesity, uncontrolled diabetes, and cardiomyopathy 
[Marshall et al., 2007].  
4.11 Pulmonary disease 
Pulmonary fibrosis, dilated cardiomyopathy, and scoliosis can compromise cardio-
respiratory function, particularly with concomitant respiratory infection or anesthesia in 
routine surgical procedures. Monitoring cardiac status and oxygenation during acute illness 
and postoperatively are mandatory, considering that ALMS patients can suddenly, without 
warning become critically hypoxic [Lynch et al., 2007, Tiwari et al., 2010]. Chronic 
obstructive airway disease and associated infection should be managed in line with 
appropriate national guidelines.  
4.12 Other 
4.12.1 Gastrointestinal 
Reflux esophagitis should be diagnosed by barium swallow or upper gastrointestinal 
endoscopy, in the presence of suggestive symptoms and treated accordingly to the guidelines.  
4.12.2 Orthopedic abnormalities 
In the presence of flat feet, scoliosis, barrel chest, kyphoscoliosis the referral to an 
orthopedist is appropriate. Some patients have had surgical intervention for scoliosis, but 
care should be taken when undertaking surgical procedures, as previously mentioned. 
4.12.3 Neurologic manifestations  
ALMS patients should be examined for: absence seizures, autistic-spectrum behavioral 
abnormalities, excessive startle, unexplained joint or muscle pain, muscle dystonia, or 
hyporeflexia.  
4.13 Prevention of secondary complications 
There should be routine pediatric immunizations, especially against flu and hepatitis B virus 
infections. 
 Families should be encouraged to seek contact with good sources of support and 
information, such as Alström Syndrome International (www.alstrom.org) or other groups 
assisting families with this rare disorder. 
5. Conclusion 
Full understanding of the phenotypic characteristics, particularly with the help of existing 
mouse models [Collin et al., 2005, Arsov et al., 2006a, 2006b] will lead to better insight into 
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the pathophysiology of ALMS1. By developing targeted therapies, certain debilitating 
aspects of ALMS could be prevented or treated earlier, improving the overall outcome in 
this complex disorder [Marshall et al., 2007]. Also, careful clinical and genetic studies can 
contribute to a better understanding of the disease evolution after different therapeutic 
attempts in Alström Syndrome. 
6. References 
Alström, C.H., Hallgren, B., Nilsson, L.B., & Åsander H. (1959). Retinal degeneration 
combined with obesity, diabetes mellitus and neurogenous deafness: a specific 
syndrome (not hitherto described) distinct from the Laurence-Moon-Bardet-Biedl 
syndrome: a clinical, endocrinological and genetic examination based on a large 
pedigree. Acta psychiatrica et neurologica Scandinavica Supplementum, Vol. 129, pp. 1-
35, ISSN: 0365-5067. 
Arsov, T., Larter, C.Z., Nolan, C.J., Petrovsky, N., Goodnow, C.C., Teoh, N..C, Yeh, M.M. & 
Farrell, G.C. (2006). Adaptive failure to high-fat diet characterizes steatohepatitis in 
Alms1 mutant mice. Biochemichal and Biophysical Research Communications. Vol. 342, 
No. 4 (April 2006), pp. 1152–1159. (a) 
Arsov, T., Silva, D.G., O'Bryan, M.K., Sainsbury, A., Lee, N.J., Kennedy, C., Manji, S.S., 
Nelms, K., Liu, C., Vinuesa, C.G., de Kretser, D.M., Goodnow, C.C.& Petrovsky, N. 
(2006). Fat Aussie—a new Alström Syndrome mouse showing a critical role for 
Alms1 in obesity, diabetes and spermatogenesis. Molecular Endocrinology. Vol. 20, 
No. 7 (July 2006), pp. 1610–1622. (b) 
Atabek, M.E. (2007). Re: "Effect of metformin and rosiglitazone in a prepubertal boy with 
Alström syndrome". Pediatric Endocrinology & Metabolism, Vol. 21, No. 1 (January 
2008): 100; author reply 100-101. 
Awazu, M., Tanaka, T., Yamazaki, K., Kato, S., Higuchi, M. & Matsuo, N. (1995). A 27-year-
old woman with Alström syndrome who had liver cirrhosis. The Keio Journal of 
Medicine. Vol. 44, No. 2 (June 1995), pp. 67–73. 
Awazu, M., Tanaka, T., Sato, S., Anzo, M., Higuchi, M., Yamazaki, K., & Matsuo, N. (1997). 
Hepatic dysfunction in two sibs with Alström syndrome: case report and          
review of the literature. American journal of medical genetics. Vol. 69, No. 1 (March  
1997), pp. 13–16.  
Badano, J.L., Mitsuma, N., Beales, P.L. & Katsanis, N. (2006). The ciliopathies: an emerging 
class of human genetic disorders. Annual Review of Genomics and Human Genetics, 
Vol.7, (September 2006), pp.125-148, ISSN: 1527-8204. 
Bell,C.J., Dinwiddie, D.L., Miller, N.A., Hateley, S.L., Ganusova, E.E., Mudge, J., Langley, 
R.J., Zhang, L., Lee, C.C., Schilkey, F.D., Sheth, V., Woodward, J.E., Peckham, H.E.,    
Schroth, G.P., Kim &R.W.,Kingsmore, S.F. (2011). Carrier testing for severe 
childhood recessive diseases by next-generation sequencing. Science. Translational . 
Medicine., 3, 65ra4. 
Benso, C., Hadjadj, E., Conrath, J. & Denis, D. (2002). Three new cases of Alström syndrome.        
Graefe's Archive for Clinical and Experimental Ophthalmology. Vol. 240, No. 8 (August 
2002), pp. 622-627. 
Boor, R., Herwig, J., Schrezenmeir, J., Pontz, B.F. & Schönberger, W. (1993). Familial Insulin 
Resistant Diabetes Associated With Acanthosis Nigricans, Polycystic Ovaries, 
Hypogonadism, Pigmentary Retinopathy, Labyrinthine Deafness, and Mental 
www.intechopen.com
 
Advances in the Study of Genetic Disorders 222 
Retardation. American Journal of Medical Genetics. Vol. 45, No. 5 (March 1993), pp. 
649-653. 
Charles, S., Moore, A., Yates, J., Green, T. & Clark, P. (1990). Alström 's syndrome: further 
evidence of autosomal recessive inheritance and endocrinological dysfunction. 
Journal of Medical Genetics. Vol. 27, No. 9 (September 1990), pp. 590–592.  
Collin, G.B., Marshall, J.D., Ikeda, A., W., So, V., Russell-Eggitt, I., Maffei, P., Beck, S., 
Boerkoel, C.F.,  Sicolo, N., Martin, M., Nishina, P.M. & Naggert, J.K. (2002). 
Mutations in ALMS1 cause obesity, type 2 diabetes and neurosensory degeneration 
in Alström syndrome. Nature Genetics. Vol. 31, (May 2002), pp. 74–78.  
Collin, G.B., Cyr, E., Bronson, R., Marshall, J.D., Gifford, E.J., Hicks, W., Murray,. SA., 
Zheng, Q.Y., Smith, R.S., Nishina, P.M. & Naggert, J.K. (2005). Alms1-disrupted 
mice recapitulate human Alström syndrome. Human Molecular Genetics. Vol. 14, 
No. 16 (August 2005), pp. 2323–2333.  
Connolly, M.B., Jan, J.E., Couch, R.M., Wong, L.T., Dimmick, J.E. & Rigg, J.M. (1991). 
Hepatic dysfunction in Alström disease. American Journal of Medical Genetics. Vol. 
40, No. 4 (September 1991), pp. 421–424.  
Deeble, V.J., Roberts, E., Jackson, A., Lench, N., Karbani, G. & Woods, C.G. (2000). The 
continuing failure to recognise Alström syndrome and further evidence of genetic 
homogeneity. Journal of Medical  Genetics. Vol.37, No.3 (March 2000), pp. 219. 
Florentzson, R., Hallén, K. & Möller, C. (2010). Alström syndrome and cochlear 
implantation. The first clinical experience. 10th International CI-conference June 27-
July 1, 2010,  Stockholm. 
Girard D. & Petrovsky, N. (2010). Alström syndrome: insights into the pathogenesis of 
metabolic disorders. Nature Reviews. Endocrinology. Vol. 7, No. 2 (February 2011), 
pp. 77-88. 
Gogi, D., Bond, J., Long, V., Sheridan, E. & Woods, C.G. (2007). Exudative retinopathy in a 
girl with Alström syndrome due to a novel mutation. The British Journal of 
Ophthalmology. Vol. 91, No. 7 (July 2007), pp. 983–984. 
Goldstein, J.L.& Fialkow, P.J. (1973). The Alström syndrome. Report of three cases with 
further delineation of the clinical, pathophysiological, and genetic aspects of the 
disorder. Medicine. Vol. 52, No. 1 (January 1973), pp. 53–71. 
Goerler, H., Warnecke, G., Winterhalter, M., Müller, C., Ballmann, M., Wessel, A., Haverich, 
A., Strüber, M. & Simon, A. (2007). Heart-lung transplantation in a 14-year-old boy 
with Alström syndrome. The Journal of Heart and Lung Transplantation. Vol. 26, No. 
11, pp: 1217-8 
Hearn, T., Renforth, G.L., Spalluto, C., Hanley, N.A., Piper, K., Brickwood, S., White, C., 
Connolly, V., Taylor, J.F.N., Russell-Eggitt, I., Bonneau, D., Walker, M. & Wilson, 
D.I. (2002). Mutation of ALMS1, a large gene with a tandem repeat encoding 47 
amino acids, causes Alström syndrome. Nature Genetics. Vol. 31, No. 1 (May 2002), 
pp. 79-83.  
Hearn, T., Spalluto, C., Phillips, V.J., Renforth, G.L., Copin, N., Hanley, N.A. & Wilson, 
D.I.(2005). Subcellular localization of ALMS1 supports involvement of centrosome 
and basal body dysfunction in the pathogenesis of obesity, insulin resistance, and 
type 2 diabetes. Diabetes. Vol. 54, No. 5 (May 2005), pp. 1581-1587. 
www.intechopen.com
 
Alström Syndrome 223 
Hoffman, J.D., Jacobson, Z., Young, T.L., Marshall, J.D. & Kaplan, P. (2005). Familial variable 
expression of dilated cardiomyopathy in Alström syndrome: a report of four sibs. 
American Journal of Medical Genetics. Vol. 135A, No. 1 (May 2005), pp. 96–98. 
Holder, M., Hecker, W. & Gilli, G. Impaired Glucose Tolerance Leads to Delayed Diagnosis 
of Alström Syndrome. Diabetes Care. Vol. 18, No. 5 (May 1995), pp. 698-700. 
Joy, T., Cao, H., Black, G., Malik, R., Charlton-Menys, V., Hegele, R.A. &  Durrington,  P.N. 
(2007). Alström syndrome (OMIM 203800): a case report and literature review. 
Orphanet Journal of Rare Diseases. Vol. 2, No. 1 (December 2007): 49, Available from 
http://www.ojrd.com/content/2/1/49. 
Khoo, E.Y., Risley, J., Zaitoun, A.M., El-Sheikh, M., Paisey, R.B., Acheson, A.G. & Mansell 
P.(2009): Alström syndrome and cecal volvulus in 2 siblings. American Journal of 
Medical Sciences. Vol. 337, No. 5 (May 2009), pp: 383-385. 
Kinoshita, T., Hanaki, K., Kawashima, Y., Nagaishi, J., Hayashi, A., Okada, S., Murakami, J.,  
Nanba, E., Tomonaga, R. & Kanzaki, S. (2003). A novel non-sense mutation in 
Alström syndrome: subcellular localization of its truncated protein. Clinical 
Pediatric Endocrinology. Vol. 12, No. 2, pp. 114. 
Knorz, V.J., Spalluto, C., Lessard, M., Purvis, T.L., Adigun, F.F., Collin, G.B., Hanley, N.A., 
Wilson, D. &, Hearn, T.(2010). Centriolar association of ALMS1 and 
likelycentrosomal functions of the ALMS motif-containing proteins C10orf90 and 
KIAA1731. Molecular biology of the cell. Vol. 1, No. 21 (November 2010), pp:: 3617-
3629. 
Kocova, M., Sukarova-Angelovska, E., Kacarska, R., Maffei, P., Milan, G. & Marshall, J.D. 
(2010). The Unique Combination of Dermatological and Ocular Phenotypes in 
Alström Syndrome: Severe Presentation, Early Onset, and Two Novel ALMS1 
Mutations. British Journal of Dermatology. (December 2010) doi: 10.1111/j.1365-
2133.2010.10157.x. [Epub ahead of print]. 
Koray, F., Dorter, C., Benderli, Y., Satman, I., Yilmaz, T., Dinccag, N. & Karsidag, K. (2001). 
Alström syndrome: a case report. Journal of Oral Science. Vol. 43, No. 3 (September 
2001), pp. 221–224.  
Lee, N., Marshall, J.D., Collin, G.B., Naggert, J.K., Chien, Y.H., Tsai, W.Y.& Hwu, W.L. 
(2009). Caloric restriction in Alström syndrome prevents hyperinsulinemia. 
American Journal of Medical Genetics Part A. Vol. 149A, No. 4 (February 2009), pp. 
666-668. 
Li, G., Vega, R., Nelms, K., Gekakis, N., Goodnow, C., McNamara, P., Wu, H., Hong, N. & 
Glynne, R. (2007). A Role for Alström Syndrome Protein, Alms1, in Kidney 
Ciliogenesis and Cellular Quiescence. PLoS Genetics. Vol. 3, No. 1 (January 2007): 
e8. doi:10.1371/journal.pgen.0030008. 
Loudon, M.A., Bellenger, N.G., Carey, C.M. & Paisey, R.B. (2009). Cardiac magnetic 
resonance imaging in Alström syndrome. Orphanet Journal of Rare Diseases. Vol. 4 
(June 2009):14. http://www.ojrd.com/content/4/1/14 
Lynch, G., Clinton, S. & Siotia, A. (2007). Anaesthesia and Alström’s Syndrome. Anaesthesia 
and Intensive Care. Vol. 35, No. 2 (April 2007), pp. 305-306. 
Maffei, P., Munno, V., Marshall, J.D., Milanesi, A., Martini, C., De Carlo, E., Mioni, R., 
Pontoni, E.,  Menegazzo, C. & Sicolo, N. (2000). GH and IGF-I Axis in Alström 
Syndrome. Journal of Endocrinological Investigation. Vol. 23 (Suppl. to No. 6), pp. 29. 
www.intechopen.com
 
Advances in the Study of Genetic Disorders 224 
Maffei, P., Boschetti, M., Orsi, I., Marshall, J.D., Paisey, R.B., Beck, S., Munno, V., Minuto, F., 
Barreca, A.M. & Sicolo, N. (2002). The IGF system in Alström Syndrome. Growth 
Hormone and IGF Research. Vol. 12, No. 4, pp. 291. 
Maffei, P., Munno, V., Marshall, J.D., Scandellari, C. & Sicolo, N. (2002). The Alström 
syndrome: is it a rare or unknown disease? Annali Italiani di Medicina Interna. Vol. 
17, No. 4 (October-December  2002), pp. 221–228. 
Maffei, P., Boschetti, M., Marshall, J.D., Paisey, R.B., Beck, S., Resmini, E., Collin, G.B., 
Naggert, J.K., Milan, G., Vettor, R., Minuto, F., Sicolo, N. & Barreca, A. (2007). 
Characterization of the IGF system in 15 patients with Alström syndrome. Clinical 
endocrinology. Vol. 66, No. 2 (February 2007), pp. 269–275. 
Makaryus, A.N., Popowski, B., Kort, S., Paris, Y. & Mangion, J. (2003). A rare case of Alström 
syndrome presenting with rapidly progressive severe dilated cardiomyopathy 
diagnosed by echocardiography. Journal of the American Society of Echocardiogr.aphy. 
Vol. 16, No. 2 (February 2003), pp. 194–196. 
Markaryus, A.N., Zubrow, M.E., Marshall, J.D., Gillam, L.D. &Mangion, J.R. (2007). Cardiac 
manifestations of Alström syndrome: echocardiographic findings. Journal of 
American Society of Echocardiography. Vol.20, No. 12, (December 2007), pp.1359-1363.  
Malm, E., Ponjavic, V., Nishina, P.M., Naggert, J.K., Hinman, E.G., Andréasson, S., Marshall, 
J.D. & Möller, C. (2008). Full-field electroretinography and marked variability in 
clinical phenotype of Alström syndrome. Archives of Ophthalmology. Vol. 126, No. 1 
(January 2008), pp. 51–57. 
Marshall, J.D., Ludman, M.D., Shea, S.E., Salisbury, S.R., Willi, S.M., LaRoche, R.G. & 
Nishina, P.M. (1997). Genealogy, natural history, and phenotype of Alström 
syndrome in a large Acadian kindred and three additional families. American 
Journal of Medical Genetics.Vol.73, No.2 (December 1997), pp. 150–161.  
Marshall, J.D., Bronson, R.T., Collin, G.B., Nordstrom, A.D., Maffei, P., Paisey, R.B., Carey, 
C., Macdermott, S., Russell-Eggitt, I., Shea, S.E., Davis, J., Beck, S., Shatirishvili, G., 
Mihai, C.M., Hoeltzenbein, M., Pozzan, G.B., Hopkinson, I., Sicolo, N., Naggert, 
J.K. & Nishina, P.M. (2005). New Alström syndrome phenotypes based on the evaluation 
of 182 cases. Archives of internal medicine. Vol. 165, No. 6 (March 2005), pp. 675–683.  
Marshall, J.D., Beck, S., Maffei, P.& Naggert, J.K. 2007(a). Alström syndrome. European 
Journal of Human Genetics. Vol. 15,  No.12 (December 2007), pp. 1193–1202.  
Marshall, J.D., Hinman, E.G., Collin, G.B., Beck, S., Cerqueira, R., Maffei, P., Milan, G., 
Zhang, W., Wilson, D.I., Hearn, T., Tavares, P., Vettor, R., Veronese, C., Martin, M., 
So, W.V., Nishina, P.M. & Naggert, J.K. (2007). Spectrum of ALMS1 variants and 
evaluation of genotype–phenotype correlations in Alström syndrome. Human 
Mutation. Vol. 28, No. 11 (November 2007), pp. 1113-1123 (b). 
Marshall, J.D., Paisey, R.B., Carey, C. & Macdermott, S. (Last update June 2010). Alström 
Syndrome. GeneReviews. NCBI Bookshelf. Available from 
http://www.ncbi.nlm.nih.gov/books/NBK1267/ 
Michaud, J.L., Héon, E., Guilbert, F., Weill, J., Puech, B., Benson, L., Smallhorn, J.F., Shuman, 
C.T., Buncic, J.R., Levin, A.V., Weksberg, R. & Brevière, G.M. (1996). Natural 
history of Alström syndrome in early childhood: Onset with dilated 
cardiomyopathy. The Journal of Pediatrics. Vol. 128, No. 2 (February 1996), pp. 225-
229. 
www.intechopen.com
 
Alström Syndrome 225 
Mihai, C.M., Catrinoiu, D.,  Marshall, J.D.,  Stoicescu, R. & Tofolean, J.T. (2008). Cilia, 
Alström Syndrome - molecular concept, mechanisms and therapeutic perspectives. 
Journal of Medicine and Life. Vol. 1, No. 3 (July-September 2008), pp. 254-261. 
Mihai, C.M., Catrinoiu, D., Toringhibel, M., Stoicescu, R.M., Negreanu-Pirjol, T. & Hancu, A. 
(2009). Impaired IGF1-GH axis and new therapeutic options in  Alström Syndrome 
patients: a case series. Cases Journal. Vol. 2, No. 1 (January 2009): 19. 
http://www.casesjournal.com/content/2/1/19. 
Minton, J.A., Owen, K.R., Ricketts, C.J., Crabtree, N., Shaikh, G., Ehtisham, S., Porter, J.R., 
Carey, C., Hodge, D., Paisey, R., Walker, M. & Barrett, T.G. (2006). Syndromic 
obesity and diabetes: changes in body composition with age and mutation analysis 
of ALMS1 in 12 United Kingdom kindreds with Alström syndrome. The Journal of 
Clinical Endocrinology and Metabolism.Vol. 91, No. 8 (August 2006), pp. 3110–3116.  
Möller, C. (2005). Alström syndrome. The National Swedish Board of Health and Welfare. Nov 
2005, Available from http//www.sos.se 
Nag, S., Kelly, W.F., Walker, M. & Connolly, V. (2003). Type 2 diabetes in Alström 
syndrome: Targeting insulin resistance with a thiazolidinedione.Endocrine 
Abstracts. Vol. 5, pp. 104. British Endocrine Society, March 2003. 
Paisey, R.B., Carey, C.M., Bower, L., Marshall, J., Taylor, P., Maffei, P. & Mansell, P. (2004). 
Hypertriglyceridaemia in Alström's syndrome: causes and associations in 37 cases. 
Clinical Endocrinology. Vol. 60, No. 2 (February 2004), pp. 228–231. 
Paisey, R. B., Hodge, D. & Williams, K. (2008). Body fat distribution, serum glucose, lipid 
and insulin response to meals in Alström syndrome. Journal of Human Nutrition and 
Dietetics. Vol. 21, No. 3 (June 2008), pp. 268-274. 
Paisey, R.B., Paisey, R.M., Thomson, M.P., Bower, L., Maffei, P., Shield, J.P., Barnett, S. & 
Marshall, J.D. (2009). Protection From Clinical Peripheral Sensory Neuropathy in  
Alström Syndrome in Contrast to Early-Onset Type 2 Diabetes. Diabetes Care. Vol. 
32, No. 3 (March 2009b), pp. 462-464. 
Paisey, R.B. (2009). New insights and therapies for the metabolic consequences of Alström 
syndrome. Current Opinion in Lipidology. Vol. 20, No. 4 (August 2009), pp. 315-230.  
Quiros-Tejeira, R.E., Vargas, J. & Ament, M.E. (2001). Early-onset liver disease complicated 
with acute liver failure in Alström syndrome. American Journal of Medical Genetics. 
Vol. 101, No. 1 (June 2001), pp. 9–11. 
Ozgül, R.K., Satman. I., Collin, G.B., Hinman, E.G., Marshall, J.D., Kocaman, O., Tütüncü, Y., 
Yilmaz, T. & Naggert, J.K. (2007). Molecular analysis and long-term clinical 
evaluation of three siblings with Alström syndrome. Clinical Genetics. Vol. 72, No.4 
(October 2007), pp. 351–356. 
Pagano, C., Romano, S.,  Maffei, P., Sicolo, N. & Vettor, R.(2008). Insulin resistance and 
diabetes in Alstrom syndrome. 5th International Scientific Congress.  ALSTRÖM 
SYNDROME. Padua – Venice , Italy, October 17-18, 2008. 
Patel, S., Minton, J.A., Weedon, M.N., Frayling, T.M., Ricketts, C., Hitman, G.A., McCarthy, 
M.I., Hattersley, A.T., Walker, M. & Barrett, T.G. (2006). Common variations in the 
ALMS1 gene do not contribute to susceptibility to type 2 diabetes in a large white 
UK population. Diabetologia, Vol. 49, No. 6 (June 2006), pp. 1209–1213.  
Russell-Eggitt, I.M., Clayton, P.T., Coffey, R., Kriss, A., Taylor, D.S. & Taylor, J.F. (1998). 
Alström syndrome. Report of 22 cases and literature review. Ophthalmology. Vol. 
105, No. 7, pp. 1274-1280. 
www.intechopen.com
 
Advances in the Study of Genetic Disorders 226 
Satman, I., Yilmaz, M.T., Gursoy, N., Karsidag, K., Dinccag, N., Ovali, T., Karadeniz, S., 
Uysal, V., Bugra, Z., Okten, A., & Devrim, S. (2002). Evaluation of insulin resistant 
diabetes mellitus in Alström syndrome: a long-term prospective follow-up of three 
siblings. Diabetes Research and Clinical Practice. Vol. 56, No. 3 (June 2002), pp. 189–
196.  
Sebag J, Albert DM & Craft JL (1984): The Alström syndrome: ophthalmic histopathology 
and renal ultrastructure. British Journal of Ophthalmology Vol. 68 No. 7, (July 1984)  
pp. 494-501. 
Sinha, S.K., Bhangoo, A., Anhalt, H., Maclaren, N., Marshall, J.D., Collin, G.B., Naggert, J.K. 
& Ten, S. (2007). Effect of metformin and rosiglitazone in a prepubertal boy with 
Alström syndrome. Journal of Pediatric Endocrinology & Metabolism, Vol. 21, No. 1 
(September 2007), pp. 1045-1052. 
Smith, J.C., McDonnell, B., Retallick, C., McEniery, C., Carey, C., Davies, J.S., Barrett, T.,  
Cockcroft, J.R. & Paisey, R (2007). Is arterial stiffening in Alström syndrome linked 
to the development of cardiomyopathy? European Journal of Clinical Investigation. 
Vol. 37, No. 2, (February 2007), pp. 99-105. 
Tai, T.S., Lin, S.Y. & Sheu, W.H.H. (2003). Metabolic Effects of Growth Hormone Therapy in 
an Alström Syndrome Patient. Hormone Research. Vol. 60, No. 6, pp. 297-301. 
Titomanlio, L., De Brasi, D., Buoninconti, A., Sperandeo, M.P., Pepe, A. & Andria, G. (2004). 
Alström syndrome: intrafamilial phenotypic variability in sibs with a novel 
nonsense mutation of the ALMS1 gene. Clinical Genetics 2004. Vol. 65, No. 2 
(February 2004), pp. 156-157. 
Tiwari, A., Awasthi, D., Tayal, S. & Ganguly, S, (2010). Alström syndrome: A rare genetic 
disorder and its anaesthetic significance. Indian Journal of Anesthesiology. Vol. 54, 
No. 2 (March 2010), pp. 154-156.  
Van den Abeele, K., Craen, M., Schuil, J. & Meire, F.M. (2001). Ophthalmologic and systemic 
features of the Alström syndrome: report of 9 cases. Bulletin de la Société Belge 
d'Ophtalmologie. Vol. 281 (2001), pp. 67–72. 
Vingolo, E.M., Salvatore, S., Grenga, P.L., Maffei, P., Milan, G. & Marshall J (2010). High-
resolution spectral domain optical coherence tomography images of alström 
syndrome. Journal pediatric ophthalmology strabismus Vol. 47: e1-e3 (May 2010)Welsh, 
L. W. Alström Syndrome: Progressive Deafness and Blindness (2007). The Annals of 
Otology, Rhinology & Laryngology. Vol. 116, Vol. 4 (April 2007), pp. 281-285. 
Worthley, M.I. & Zeitz, C.J. (2001). Case of Alström syndrome with late presentation dilated  
cardiomyopathy. Internal Medicine Journal. Vol. 31, No. 9 (December 2001), pp. 569-
570. 
Wu, W.C., Chen, S.C., Dia, C.Y., Yu, M.L., Hsieh, M.Y., Lin, Z.Y., Wang, L.Y., Tsai, J.F. & 
Chang, W.Y. (2002). Alström Syndrome with Acute Pancreatitis: A Case Report. 
The Kaohsiung Journal of Medical Sciences. Vol. 19, No. 7 (July 2003), pp. 358-360. 
Zubrow, M.E., Makaryus, A., Marshall, J.D., Horowitz, S., Gillam, L.D. & Mangion, J.R. 
(2006). Echocardiographic Features of the Cardiomyopathy Associated With 
Alström Syndrome: A Retrospective Review. American Society for Echocardiology 
Scientific Sessions, Baltimore, MD, June, 2006. 
www.intechopen.com
Advances in the Study of Genetic Disorders
Edited by Dr. Kenji Ikehara
ISBN 978-953-307-305-7
Hard cover, 472 pages
Publisher InTech
Published online 21, November, 2011
Published in print edition November, 2011
InTech Europe
University Campus STeP Ri 
Slavka Krautzeka 83/A 
51000 Rijeka, Croatia 
Phone: +385 (51) 770 447 
Fax: +385 (51) 686 166
www.intechopen.com
InTech China
Unit 405, Office Block, Hotel Equatorial Shanghai 
No.65, Yan An Road (West), Shanghai, 200040, China 
Phone: +86-21-62489820 
Fax: +86-21-62489821
The studies on genetic disorders have been rapidly advancing in recent years as to be able to understand the
reasons why genetic disorders are caused. The first Section of this volume provides readers with background
and several methodologies for understanding genetic disorders. Genetic defects, diagnoses and treatments of
the respective unifactorial and multifactorial genetic disorders are reviewed in the second and third Sections.
Certainly, it is quite difficult or almost impossible to cure a genetic disorder fundamentally at the present time.
However, our knowledge of genetic functions has rapidly accumulated since the double-stranded structure of
DNA was discovered by Watson and Crick in 1956. Therefore, nowadays it is possible to understand the
reasons why genetic disorders are caused. It is probable that the knowledge of genetic disorders described in
this book will lead to the discovery of an epoch of new medical treatment and relieve human beings from the
genetic disorders of the future.
How to reference
In order to correctly reference this scholarly work, feel free to copy and paste the following:
Cristina Maria Mihai, Jan D. Marshall and Ramona Mihaela Stoicescu (2011). Alstro ̈m Syndrome, Advances in
the Study of Genetic Disorders, Dr. Kenji Ikehara (Ed.), ISBN: 978-953-307-305-7, InTech, Available from:
http://www.intechopen.com/books/advances-in-the-study-of-genetic-disorders/alstro-m-syndrome
© 2011 The Author(s). Licensee IntechOpen. This is an open access article
distributed under the terms of the Creative Commons Attribution 3.0
License, which permits unrestricted use, distribution, and reproduction in
any medium, provided the original work is properly cited.
